Abstract :

Carbamazepine is used to control and treat bipolar 1 disorder’s acute manic and mixed episodes, trigeminal neuralgia, and epilepsy. Generalized tonic seizures (grand mal), mixed seizure patterns, and partial seizures with complicated sympatomatology (psychomotor, temporal lobe) are the only indications for epilepsy. Trigeminal neuralgia or tic douloureux are first-line conditions for which carbamazepine is FDA-recommended. In individuals with acute manic or mixed episodes of bipolar 1 mania, a comprehensive evaluation demonstrates the effectiveness of carbamazepine extended release. Carbamazepine is contraindicated in patients with bone marrow depression and hypersensitivity to this drug or tricyclic compounds such as amitriptyline. Dizziness, sleepiness, ataxia, nausea, and vomiting are some of the most typical adverse effects of carbamazepine. With the ability to penetrate the placenta and pass through breast milk in nursing infants, carbamazepine necessitates a choice between stopping the medication in the mother or stopping nursing. Different analytical techniques developed and validated as per ICH guidelines for the determination of carbamazepine, including High performance liquid chromatography (HPLC), Ultra performance liquid chromatography (UPLC), mass spectrometric, Liquid chromatography-Mass spectroscopy (LC-MS), and UV-Spectrophotometry has been explained in this article as it is important to analyze the drug content and % purity  in bulk and Pharmaceutical formulations for quality control purpose.

---

Keywords :

HPLC, ICH., Seizure, UPLC, UV-Spectrophotometric methods

---

References :

1. Tripathi KD. Drugs for Central Nervous System, Essentials of Medical Pharmacology. New Delhi: Jaypee, 2013; 415-451.
2. David AW, Thomas LL. Foye’s principle of medicinal chemistry, Lippincott Williams and Wilkins, 2002; 384-92.
3. Lawrence B, John L. Goodman and Gilman’s, Pharmacotherapy of the epilepsies, the pharmacological basis of therapeutics, McGraw-Hill Health profession division, 1995,473-498.
4. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and dale’s Pharmacology. Elsevier Churchill Livingstone, London, 2007; 579-84.
5. Indian Pharmacopoeia. Ministry of health and family welfare government of India. The Controller Publication, New Delhi,Vol. 1, 2010; 977-8.
6. Borse MP, Mulgund SV. UV Spectrophotometric estimation of carbamazepine in bulk and tablet dosage form. Scholars Res Library Pharm Lett, 2015; 7, 272-5.
7. Mowafy HA, Alanazi FK. Development and Validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma. Saudi Pharm J, 2012; 20, 29-34.
8. Gupta AK, Patel PK. Analytical method validation of stability-indicating HPLC method for determination of assay of carbamazepine CR tablets. Global Res Anal, 2013, 2: 8-9.
9. Datar PA. Quantitative bioanalytical and analytical method development of dibenzepne derivative; carbamazepine: a review, J Pharm Anal, 201; 5; 213-22.
10. Om khaede, Shubham Doifode Tanmay Dongaonkar and Prafulla tathe. Development and validation of UV-visible spectroscopic method for the estimation of carbamazepine in bulk and tablet dosage form.Wjpr, 2020; 9; 938-947.
11. Manoj P, Borse sugandha V, Mulgund. UV-Spectrophotometric estimation of carbamazepine in bulk and tablet dosage form, Scholar research library, 2015; 5; 272-275.
12. Nityanand zadbuke, Sadhana shahi, Ajit jadhav, Santosh borde. Development and validation of UV-Visible spectroscopic method for estimation of carbamazepine in bulk and tablet dosage form. Int J Pharm Sci.2015; 8; 0975-1491.
13. Saeid Mezail Mawazi, Sinan mohammed abdullahi AL-Mahmood. Development and validation of UV-Vis Spectroscopic method of assay of carbamazepine in microparticles., Int J App pharm. 2019;11;34-37.
14. Padma A, Dr. Thejomoorthy K, Snehith B. Estimation of carbamazepine in bulk and pharmaceutical dosage form by zero order and  area under the curve UV  spectrophotometric methods, IJSES, 2019;3; 8-11.
15. Emrah Dural, Burhanettincigdem.Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study. Istanbul J Pharm, 2019; 1; 6-15.
16. Essam Ezzeldin, Shahat A. Development and validation of an HPLC method for the determination of carbamazepine in human plasma, Life science journal, 2013; 4 ; 2159-2163.
17. Johnston C. Kand Lester G. H. A simple procedure for the determination of carbamazepine in plasma by high pressure-liquid chromatography. Annals of clinical biochemistry,1979; 6; 213-216.
18. Marta De-Diego, Esteban Pino. A validated LC method for determination of carbamazepine in saliva. J. Chill. Chem. 2022;2; 0717-9707.
19. Fatma Demirkaya, Yucel Kadioglu. Determination of carbamazepine using RP-HPLC method in pharmaceutical preparations, Fabad J. Pharm. 2005; 30; 78-82.
20. Note for guidance on validation of analytical procedures: text and methodology. European Medicines Agency, 1995: 1-15.
21. International Conference on Harmonization (ICH), Q2A. Validation of analytical procedures: Methodology. Geneva, 1994.